Dr Reddy's semaglutide relaunch in Canada set for November after an ingredient problem

The Dr Reddy's semaglutide relaunch in Canada is set for November, the company said on October 23, after a problem with the active ingredient pulled its generic pen from supply only months after launch. The restart depends on validation of the fixed ingredient process, so the date is a target. Here is what happened, what the company has and has not said, and what the gap means for Canadian pharmacies, patients and drug plans.

How the first Canadian generic went quiet

Health Canada authorised the Dr Reddy's generic semaglutide injection on April 28, 2026, making it the first company cleared to sell a generic version of the injection in Canada, PharmTech reported. The company announced the commercial launch on May 15. It makes the active ingredient in house, and a partner, OneSource Specialty Pharma, fills and finishes the pens. Chief executive Erez Israeli spoke at the time about wider access for people managing diabetes. Within weeks, though, the supply chain behind that launch ran into trouble. The company has since said that some batches were found to be out of specification because of an issue with the active pharmaceutical ingredient used to make them.

In its results release for the quarter to September, filed with the US Securities and Exchange Commission on October 23, Dr Reddy's said "certain batches of semaglutide were found to be out of specification due to an issue associated with the active pharmaceutical ingredient (API) used in the product, as communicated earlier." It added that "appropriate measures are being taken to ensure product quality and resumption of supplies." The problem had already hit the accounts. Results for the April to June quarter carried a provision of ₹2,397 million for inventory and related costs tied to the ingredient, the release shows. The company says its generic semaglutide is now approved in 10 countries, including Canada and India.

The November target and its condition

On the earnings call the same day, Israeli said the company "remains confident of resuming semaglutide supply in November 2026, pending successful validation," according to a GuruFocus summary of the call. CNBC TV18 reported that he said the scale up problem with the ingredient had been fixed and that Dr Reddy's was working with its partners to bring the product back. Validation is the step where a maker shows, with test batches, that a changed process reliably turns out material that meets its specification. Until that is done, the November date is a target rather than a promise. The company has not published a day of return or the volume it expects to ship in the first weeks of the Dr Reddy's semaglutide relaunch.

Until that is done, the November date is a target rather than a promise.

Canada is first in line. Most of the early volume is meant for Canada, with some for Latin America and a small amount for Africa, according to the call summary, and CNBC TV18 reported plans to launch in nine more markets. Canada matters because it was the company's first launch of the product in a large, high income market. A long absence could give other suppliers time to win shelf space in pharmacies and listings with drug plans, and those positions are hard to take back. For the company, the Dr Reddy's semaglutide relaunch is also a test of whether it can scale a complex peptide ingredient on a commercial timetable, which matters for every market it plans to enter next.

What the gap means for patients and pharmacies

For people in Canada who were given the Dr Reddy's pen, the gap is a supply problem, not a reason to stop treatment. A pharmacist can dispense the brand or another authorised version where one is in stock, and a prescriber can confirm that the plan still fits. The catch is cost. Generic entry is what pushes prices down, so a missing generic can leave patients with private coverage or high copays paying more than they otherwise would. Public and private drug plans that had begun to steer claims toward the lower priced product may see costs drift back up while supply is paused. None of the reports set out how many Canadian patients had been switched to the generic.

Pharmacies that stocked the generic should ask their distributor whether any units on hand are affected, since the results release does not list Canadian batch numbers. Keeping patients informed matters too. A switch from one version to another is routine for a pharmacist, but a patient who sees a new pen may worry about whether it is the same medicine. When the generic returns, the same conversation will happen in reverse. Readers following pens, plants and shortages will recognise the pattern: in India the company turned to new brands made by a partner while its own supply was fixed, as Peptide Town reported on October 23. The ingredient at the root of both problems is the same.

Key dates for the Dr Reddy's semaglutide relaunch

The timeline below sets out the verified dates. Two gaps stand out. The release does not say when the out of specification batches were found in relation to the Canadian launch, and it does not say whether any product already dispensed in Canada came from those batches. The company describes the issue as one it communicated earlier, but the public results release gives no Canadian detail. Patients who want certainty about a pen they hold can ask their pharmacist to check the batch with the distributor. Prescribers have no new clinical guidance to act on, because the company has framed this as a manufacturing and supply problem rather than a safety finding in patients.

A gap in legal supply can also feed the gray market. When a lower priced version disappears, some buyers look online for cheap semaglutide from sellers who operate outside Canadian rules, where there is no way to check the ingredient, the storage or even whether the pen is real. That risk is higher with a peptide that must be kept cold and made to tight standards. Our gray market coverage follows those channels without naming any seller. The safer route is to stay with a licensed pharmacy and a valid prescription, even if that means a short switch to another authorised version while the generic is away from the shelf.

Conclusion

The Dr Reddy's semaglutide relaunch in Canada is targeted for November 2026, pending validation of a fixed ingredient process, after some batches failed their specification. The company has not given a day, volumes or a Canadian batch list. Patients should keep treatment going through their pharmacy and ask whether another authorised version is available until the generic returns.